-
AngioDynamics Names Joseph M. DeVivo President, CEO
Tuesday, August 16, 2011 - 7:31am | 93The Board of Directors of AngioDynamics (NASDAQ: ANGO) appointed Joseph M. DeVivo President and Chief Executive Officer, effective Sept. 7, 2011. Mr. DeVivo most recently served as Global President of Smith & Nephew Orthopedics (NYSE: SNN) and previously served as President and Chief Executive...
-
After-Hours Gainers
Monday, August 15, 2011 - 4:54pm | 115Fabrinet (NYSE: FN) gained over 10% in after-hours trading after reporting positive Q4 earnings. Minco Gold Corp (NYSE: MGH) gained over 6% in after-hours trading. Pharmaceutical Product Development (NASDAQ: PPDI) raised over 5% during after-hours trading after buyout talks with the Carlyle Group...
-
Options Brief: Varian Medical Systems
Monday, August 15, 2011 - 10:51am | 79Shares of Varian Medical Systems (NYSE: VAR) are higher on the session by 0.63%, trading at $55.79. Overall put volume is now running at 2.05x the daily average, with 14% of all puts traded being purchases on the offer. 1,001 contracts have traded on the session so far. Varian Medical Systems,...
-
UPDATE: Rodman & Renshaw Upgrades Stryker from Market Perform to Market OutPerform
Monday, August 15, 2011 - 10:12am | 107Rodman & Renshaw has published a research report on Stryker Corporation (NYSE: SYK) upgrading the medical device developer from Market Perform to Market OutPerform. In the report, Rodman & Renshaw wrote, "We are upgrading Stryker to a Market OutPerform rating and a 12-month PT of $56. Our...
-
UPDATE: Rodman & Renshaw Upgrades NuVasive from Market Perform to Market Outperform With a PT of $33
Monday, August 15, 2011 - 10:06am | 100Rodman & Renshaw has published a research report on NuVasive (NASDAQ: NUVA) upgrading the company from Market Perform to Market Outperform. In the report, Rodman & Renshaw wrote, "We are upgrading NuVasive to a Market OutPerform rating and a 12-month PT of $33. Our earlier rating was a...
-
UPDATE: Rodman & Renshaw Upgrades Abiomed Inc from Market Underperform to Market Perform
Monday, August 15, 2011 - 10:00am | 102Rodman & Renshaw has published a report on Abiomed Inc (NASDAQ: ABMD) upgrading the stock as it reached the PT. In the report, Rodman & Renshaw wrote, "We are upgrading ABMD to a Market Perform rating. Our earlier rating was a Market UnderPerform with a $10 PT. ABMD stock recently hit our...
-
Rodman & Renshaw Upgrades Edwards Lifesciences from Underperform to Market Perform
Monday, August 15, 2011 - 9:55am | 102Rodman & Renshaw has published a research report on Edwards Lifesciences Corp (NYSE: EW) upgrading the company. In the report, Rodman & Renshaw wrote, "We are upgrading Edwards LifeSciences to a Market Perform rating. Our earlier rating was an UnderPerform with a $66 PT. The stock recently...
-
Study Shows Medtronic InterStim® Therapy Improves Bowel Control and Related Quality of Life Issues at Three Years
Monday, August 15, 2011 - 9:06am | 494Medtronic (NYSE: MDT) announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality of life in a majority of patients with chronic fecal incontinence at three...
-
Rodman & Renshaw Upgrades Stryker to Market Outperform, $56 PT
Monday, August 15, 2011 - 8:28am | 27Rodman & Renshaw has upgraded Stryker (NYSE: SYK) from Market Perform to Market Outperform and has established a $56 price target.
-
Rodman & Renshaw Upgrades NuVasive To Market Outperform, $33 PT
Monday, August 15, 2011 - 8:23am | 27Rodman & Renshaw has upgraded NuVasive (NASDAQ: NUVA) from Market Perform to Market Outperform and has established a $33 price target.
-
Rodman & Renshaw Upgrades Edward Lifesciences To Market Perform, $66 PT
Monday, August 15, 2011 - 8:20am | 27Rodman & Renshaw has upgraded Edwards Lifesciences (NYSE: EW) from Underperform to Market Perform and has established a $66 price target.
-
Rodman & Renshaw Upgrades Abiomed to Market Perform, $10 PT
Monday, August 15, 2011 - 8:19am | 27Rodman & Renshaw has upgraded Abiomed (NASDAQ: ABMD) from Market Underperform to Market Perform and has established a $10 price target.
-
UPDATE: J.P. Morgan Lowers Price Target On Medtronic To $39
Monday, August 15, 2011 - 8:18am | 67According to J.P. Morgan, Medtronic (NYSE: MDT) price target is lowered to $39. J.P. Morgan said that Medtronic is scheduled to report fiscal 1Q12 results Tuesday, August 23 before the market open. “On the top line, we forecast sales of $4.064B (+7.7%, +1.7% organic), roughly $80M above Street...
-
Citi Lowers PT on Medtronic to $40
Monday, August 15, 2011 - 7:50am | 111Citi is out with its report today on Medtronic (NYSE: MDT), lowering its PT to $46 from $40. In its report, Citi writes, "Our last target price change occurred before the recent market correction which has led to a 15% reduction in the peer group multiple. Hence, our target price drops from $46 to...
-
Citigroup Lowers PT on Medtronic To $40
Monday, August 15, 2011 - 6:04am | 25Citigroup has lowered the price target on Medtronic (NYSE: MDT) from $46 to $40 and maintains its Buy rating.